Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

Efficacy and Safety of Polisorb® MP in the Complex Therapy of Patients With Atopic Dermatitis

A legfontosabb adatok

Ki végzi
Polisorb Joint Stock Company
Hol
Oroszország7 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
161 fő vett részt
Kezdés
2024. ápr. 10.
Befejezés
2024. nov. 28.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Colloidal Silicon Dioxide
  • Basic Therapy for Atopic Dermatitis
A regiszteradat frissítve
2026. november 10.

Ki vehet részt

Életkor
18 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 7 feltétel megnézéseKevesebb

Ki vehet részt

  • Adults aged 18 to 65 years
  • Diagnosis of mild to moderate atopic dermatitis
  • Compliance with the study protocol requirements
  • Provision of written informed consent

Ki nem vehet részt

  • Contraindications to the study treatment or concomitant therapy, as specified in the study protocol
  • Failure to meet the inclusion criteria
  • Other conditions or circumstances that, according to the study protocol, could interfere with participation or the assessment of treatment efficacy and safety

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This multicenter, open-label, randomized Phase III clinical trial evaluated the efficacy and safety of adding Polisorb® MP, an oral colloidal silicon dioxide adsorbent, to basic therapy in adults with mild to moderate atopic dermatitis.

A teljes eredeti leírásKevesebb

The study included 161 patients in the efficacy analysis. Participants were randomly assigned to receive either basic therapy alone (81 patients) or basic therapy in combination with Polisorb® MP (80 patients). Basic therapy included skin care with emollients and pharmacological treatment, including cetirizine and topical pimecrolimus. The treatment period lasted 14 days, followed by an observation period. The primary endpoint was the change in the SCORAD index from baseline to Day 14. Itch intensity, dermatology-related quality of life, EASI and IGA scores were also assessed.

Both groups showed improvement in disease severity during treatment. The mean SCORAD score decreased by 21.5 points in patients receiving Polisorb® MP in addition to basic therapy, compared with 17.7 points in patients receiving basic therapy alone. The difference between the groups was statistically significant (p = 0.0028), favoring the addition of Polisorb® MP. Improvements in itch intensity and IGA scores also favored combination therapy, while differences between groups in EASI changes and changes in dermatology-related quality of life were not statistically significant.

A total of 34 adverse events were reported in 26 patients. No serious adverse events or deaths were reported. Gastrointestinal events, particularly constipation, were more frequent in the Polisorb® MP group. Other reported events included difficulty with defecation, abdominal discomfort, bloating, dry mouth and nausea. No new or unexpected safety concerns specific to Polisorb® MP were identified during the study.

The findings indicate that adding Polisorb® MP to basic therapy was associated with a greater reduction in SCORAD scores over 14 days than basic therapy alone. The results should be interpreted in the context of the open-label design and the short treatment period.

A vizsgálat 2 csoportja

  • Basic Therapy AloneMár használt kezelés, összehasonlításként

    Participants received basic therapy for atopic dermatitis, including emollient skin care and pharmacological treatment with cetirizine and topical pimecrolimus. The treatment period lasted 14 days, followed by an observation period.

    Kezelés: Basic Therapy for Atopic Dermatitis

  • Basic Therapy in Combination with Polisorb® MPA vizsgált kezelés

    Participants received Polisorb® MP in combination with basic therapy for atopic dermatitis, including emollient skin care and pharmacological treatment with cetirizine and topical pimecrolimus. The treatment period lasted 14 days, followed by an observation period.

    Kezelés: Colloidal Silicon Dioxide és Basic Therapy for Atopic Dermatitis

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Multicenter Open-label Randomized Trial With an Active Control Group to Evaluate the Efficacy and Safety of Polisorb® MP in the Complex Therapy of Patients With Atopic Dermatitis
A regiszteradat frissítve
2026. november 10.